TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodesResearch in context

Background: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically important for B cell activity in lymph nodes but little is known about the in vivo imp...

Full description

Bibliographic Details
Main Authors: Mariane H. Schleimann, Maria-Louise Kobberø, Line K. Vibholm, Kathrine Kjær, Leila B. Giron, Kathleen Busman-Sahay, Chi Ngai Chan, Michael Nekorchuk, Manuel Schmidt, Burghardt Wittig, Tine E. Damsgaard, Peter Ahlburg, Michel B. Hellfritzsch, Kaja Zuwala, Frederik H. Rothemejer, Rikke Olesen, Phillipp Schommers, Florian Klein, Harsh Dweep, Andrew Kossenkov, Jens R. Nyengaard, Jacob D. Estes, Mohamed Abdel-Mohsen, Lars Østergaard, Martin Tolstrup, Ole S. Søgaard, Paul W. Denton
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419304402